History

2011: A new rights issue was completed in May 2011 of 7 040 000 SEK. The proceeds are used for final development, production set up and launch of  first product, TK 210/hem. After completion of the rights issue the company was listed on AktieTorget ( Equities Market Place).

2010: A rights issue of totally 2.6 MSEK was finalized in June 2010.The money will cover the costs for the final development phase and basic clinical documentation of the ELISA test.

An agreement was signed between AroCell and EuroDiagnostica in July 2010 for production of the TK
ELISA.

2009: Third round of investments, April 2009. for the first step in the development of a clinically usefull TK ELISA.

2008: Prototype ELISA assay developed

2007: Introducing our first product for immunohistochemistry and prototype ELISA assay. The first product based on our patented cell proliferation marker XPA-210 is now availabe for customers in immunohistochemistry. Find more information here, under “Products & technology / Immunohistochemistry”.
Please visit our distributor at: www.immunsystem.com to place an order (webpage will be updated with our products).

2006: Changes name to AroCell AB

2006: Eureka project acceptance and funding from Vinnova

2006: Prize winning in Venture Cup, (2nd and 3rd stage). Finalist in “Swedish Spin-off Company of the year” (Årets avknoppningsföretag, February 2007). AroCell was recently named one of this years six finalists in the annual award This award is organized by IVA (Royal Swedish Academy of Engineering Sciences) and Connect Sweden. Nominees are all spin-off companies from Swedish universities and institutes. The winner will be announced later this spring, and is selected by a jury consisting of members from IVA and Connect Sweden based on the uniqueness of the product, the business model, the management team and overall commercial potential. Read more (in Swedish) at: www.connectsverige.se and http://www.nyteknik.se/art/48926.

2005: First financing.

2003: Founded as “Xi Bao Research AB” by Per Matsson (Phadia AB), Qimin He, Sven Skog and Bernhard Tribukait (Karolinska Institute), Arne Ferstad (external consultant) and Staffan Eriksson (Swedish University of Agricultural Sciences).

1995: Patent application for new tumor marker (patents granted 2000 and 2001)